{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:18:31Z","timestamp":1788286711676,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Current guidelines recommend\n                    <jats:italic>BRCA1<\/jats:italic>\n                    and\n                    <jats:italic>BRCA2<\/jats:italic>\n                    genetic testing for individuals with a personal or family history of certain cancers. Three\n                    <jats:italic>BRCA1\/2<\/jats:italic>\n                    founder variants \u2014 185delAG (c.68_69delAG), 5382insC (c.5266dupC), and 6174delT (c.5946delT) \u2014 are common in the Ashkenazi Jewish population. We characterized a cohort of more than 2,800 research participants in the 23andMe database who carry one or more of the three Ashkenazi Jewish founder variants, evaluating two characteristics that are typically used to recommend individuals for\n                    <jats:italic>BRCA<\/jats:italic>\n                    testing: self-reported Jewish ancestry and family history of breast, ovarian, prostate, or pancreatic cancer. Of the 1,967 carriers who provided self-reported ancestry information, 21% did not self-report Jewish ancestry; of these individuals, more than half (62%) do have detectable Ashkenazi Jewish genetic ancestry. In addition, of the 343 carriers who provided both ancestry and family history information, 44% did not have a first-degree family history of a\n                    <jats:italic>BRCA<\/jats:italic>\n                    -related cancer and, in the absence of a personal history of cancer, would therefore be unlikely to qualify for clinical genetic testing. These findings may help inform the discussion around broader access to\n                    <jats:italic>BRCA<\/jats:italic>\n                    genetic testing.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-63466-x","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T06:03:43Z","timestamp":1588745023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Identifying Ashkenazi Jewish BRCA1\/2 founder variants in individuals who do not self-report Jewish ancestry"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0684-0441","authenticated-orcid":false,"given":"Ruth I.","family":"Tennen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Laskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram L.","family":"Koelsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce Y.","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"63466_CR1","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2020, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf."},{"key":"63466_CR2","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1097\/AOG.0000000000002296","volume":"130","author":"Committee on Practice Bulletins\u2013Gynecology","year":"2017","unstructured":"Committee on Practice Bulletins\u2013Gynecology. Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. Obstet Gynecol 130, e110\u2013e126 (2017).","journal-title":"Obstet Gynecol"},{"key":"63466_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck, T. R., Kauff, N. D. & Domchek, S. M. Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers. JNCI J. Natl. Cancer Inst. 101, 80\u201387 (2009).","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"63466_CR4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jama.2019.10987","volume":"322","author":"DK Owens","year":"2019","unstructured":"Owens, D. K. et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 322, 652\u2013665 (2019).","journal-title":"JAMA"},{"key":"63466_CR5","unstructured":"Gabai-Kapara, E. et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc. Natl. Acad. Sci. U.S.A. (2014)."},{"key":"63466_CR6","doi-asserted-by":"crossref","unstructured":"Manchanda, R. et al. Population Testing for Cancer Predisposing BRCA1\/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial. JNCI J. Natl. Cancer Inst. 107 (2014).","DOI":"10.1093\/jnci\/dju379"},{"key":"63466_CR7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/bjc.2013.309","volume":"109","author":"KA Metcalfe","year":"2013","unstructured":"Metcalfe, K. A. et al. A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing. Br. J. Cancer 109, 777\u2013779 (2013).","journal-title":"Br. J. Cancer"},{"key":"63466_CR8","doi-asserted-by":"crossref","unstructured":"Manickam, K. et al. Exome Sequencing\u2013Based Screening for BRCA1\/2 Expected Pathogenic Variants Among Adult Biobank Participants. JAMA Netw. Open. 1 e182140 (2018).","DOI":"10.1001\/jamanetworkopen.2018.2140"},{"key":"63466_CR9","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B. et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 317, 2402\u20132416 (2017).","journal-title":"JAMA"},{"key":"63466_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/jama.2014.12483","volume":"312","author":"M-C King","year":"2014","unstructured":"King, M.-C., Levy-Lahad, E. & Lahad, A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 312, 1091\u20131092 (2014).","journal-title":"JAMA"},{"key":"63466_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3747\/co.24.3828","volume":"24","author":"MR Akbari","year":"2017","unstructured":"Akbari, M. R., Gojska, N. & Narod, S. A. Coming of age in Canada: a study of population-based genetic testing for breast and ovarian cancer. Curr. Oncol 24, 282\u2013283 (2017).","journal-title":"Curr. Oncol"},{"key":"63466_CR12","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/cncr.24200","volume":"115","author":"M Hall","year":"2009","unstructured":"Hall, M. et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115, 2222\u201333 (2009).","journal-title":"Cancer"},{"key":"63466_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2501\/IJMR-2015-014a","volume":"57","author":"M Callegaro","year":"2015","unstructured":"Callegaro, M., Murakami, M. H., Tepman, Z. & Henderson, V. Yes\u2013no Answers versus Check-all in Self-Administered Modes: A Systematic Review and Analyses. Int. J. Mark. Res 57, 203\u2013224 (2015).","journal-title":"Int. J. Mark. Res"},{"key":"63466_CR14","doi-asserted-by":"publisher","unstructured":"Manchanda, R. et al. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. Am. J. Obstet. Gynecol., https:\/\/doi.org\/10.1016\/j.ajog.2017.06.038 (2017).","DOI":"10.1016\/j.ajog.2017.06.038"},{"key":"63466_CR15","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamaoncol.2015.2340","volume":"1","author":"EF Long","year":"2015","unstructured":"Long, E. F. & Ganz, P. A. Cost-effectiveness of Universal BRCA1\/2 Screening: Evidence-Based Decision Making. JAMA Oncol 1, 1217\u20131218 (2015).","journal-title":"JAMA Oncol"},{"key":"63466_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00257-5","volume":"8","author":"C Tian","year":"2017","unstructured":"Tian, C. et al. Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections. Nat. Commun. 8, 599 (2017).","journal-title":"Nat. Commun."},{"key":"63466_CR17","doi-asserted-by":"publisher","unstructured":"Durand, E. Y., Do, C. B., Mountain, J. L. & Macpherson, J. M. Ancestry Composition: A Novel, Efficient Pipeline for Ancestry Deconvolution. bioRxiv 010512, https:\/\/doi.org\/10.1101\/010512 (2014).","DOI":"10.1101\/010512"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63466-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63466-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63466-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T05:02:47Z","timestamp":1670302967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63466-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["63466"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-63466-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/19001032","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"20 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.I.T., S.B.L., B.L.K, M.H.M. and J.Y.T. are employees of and have stock, stock options, or both, in 23andMe, Inc. The authors declare no other financial or non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7669"}}